Wire · opportunities
Trump Order Gives Psychedelic Therapy a Boost
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 July 2026 · Fusion42 review
Trump's April 2026 executive order accelerates psychedelic therapy research and FDA approval pathways, allocates $50m to state research efforts, and signals government backing for psilocybin and MDMA trials. Experts caution that expanded access requires larger clinical trials, trained clinician networks, standardised reimbursement frameworks, and science-driven regulatory decisions rather than political momentum.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you're building psychedelic-assisted therapy delivery—clinical ops, patient matching, therapist training platforms—the FDA approval clock just started moving, and the bottleneck isn't regulatory, it's clinician supply and reimbursement. You have 12-24 months to own the infrastructure layer before MDMA and psilocybin approvals hit, because the approved drugs won't work without trained providers and insurance coverage ready.
◆ Coverage
1 source · 22 Jul 2026
◆ Related on Wire
◆ Topics